Prednisol Drops

Prednisol Drops



Dropping bottle containing 15 mL.



Prednisolone (as acetate) 1 g
Excipients q.s. 100 ml


Steroidal intermediate-acting anti-inflammatory drug.


Steroidal intermediate-acting anti-inflammatory drug. Mainly indicated for the treatment of three pathological conditions: 1) replacement of glucocorticoids in case of adrenal failure, 2) as anti-inflammatory agent, and 3) as immunosuppressant agent. Glucocorticoids are used to treat, among other conditions, endocrine conditions (e.g.: adrenal failure), systemic lupus erythematosus, allergic conditions, respiratory diseases (feline asthma), skin disorders (pemphigus, allergic contact dermatitis, eosinophilic granuloma), autoimmune hematological disorder (thrombocytopenias, autoimmune hemolytic anemia), neoplastic diseases, central nervous system disorders (raised intracranial pressure, traumas), gastrointestinal disorders (ulcerative colitis, lymphoplasmacytic enteritis) and renal conditions (nephrotic syndrome).




20 drops of the product (1 ml) are equivalent to 10 mg of prednisolone.
The doses of prednisolone are highly variable according to the therapeutic indication they are intended for.
The following can be used as a guideline; however, the dose may vary at the discretion of the treating veterinarian:
0.5 to 3 mg/kg, equivalent to 1 to 6 drops/kg body weight.
For complementary therapy in the treatment of neoplasms (brain tumors, lymphomas,
myelomas, macroglobulinemia, etc.): 0.5 to 1 mg/kg daily, and then change to alternate day
therapy. The dose must be adjusted according to the patient’s needs.
For complementary treatment in case of respiratory disorders (chronic bronchitis, allergic bronchitis, trachea collapse, pneumonitis, hypersensitivity to pulmonary parasites): 0.5 to 1.5 mg/kg daily. Later, an alternate day therapy can be implemented. For complementary therapy in hepatic disorders (cholangitis, lymphocytic-plasmacytic hepatitis, toxic liver diseases): 0.5 to 2 mg/kg/day. In complementary therapy in case of gastrointestinal disorders (eosinophilic colitis, eosinophilic enteritis, lymphoplasmacytic enteritis, ulcerative colitis, dietary allergy or intolerance, endotoxemia secondary to GDV, intestinal lymphangiectasia): 0.5 to 2 mg/kg/day.
For adrenal conditions (adrenocortical failure due to adrenalectomy caused by tumor or with a different origin, azotemia): 1 to 2 mg/kg/day. For central nervous system disorders (granulomatous meningoencephalitis, reticulosis, hydrocephalus, spinal cord compression syndrome, spondylopathy, wobbler syndrome, aseptic suppurative meningitis): 0.5 to 3 mg/kg, once or twice a day. For skin disorders or immune-mediated disorders (urticaria and angioedema, canine atopy, allergic dermatitis, type II hypersensitivity, lupus erythematosus): 0.5 to 4 mg/kg.
As immunosuppressive agent: 2 to 4 mg/kg daily divided into two doses. For complementary therapy in the treatment of respiratory disorders (allergic bronchitis, feline asthma): 0.5 to 3 mg/kg/day. For complementary therapy in the treatment of gastrointestinal disorders (lymphoplasmacytic enteritis, inflammatory intestinal disease): 1 to 2 mg/kg daily divided into two doses. In case of chronic diarrhea use 2 to 4 mg/kg daily during 2 weeks. Reduce the dose by half within the following two weeks, and continue administering said dose for about three months, according to the clinical response.
For complementary treatment of plasma cell gingivitis-pharyngitis: 1 to 2 mg/kg/day. For dermatological conditions (flea allergies, idiopathic feline miliary dermatitis, eosinophilic granuloma, eosinophilic ulcer): 1 to 2 mg/kg, once or twice a day. For complementary therapy in the treatment of feline neoplasms (malignant lymphoma, acute lymphocytic leukemia, mastocytomas): 1 to 4 mg/kg/day.
In all cases, the lowest dose and the treatment schedule which will maintain the desired effect should be reached.


Do not administer to animals suffering from systemic fungal infections. Do not use in pregnant or lactating animals.


- Argentina
- Paraguay
- Uruguay
- Perú
- Panamá
- Ecuador
- Guatemala
- Emiratos Árabes Unidos